MiNK Therapeutics, Inc. Share-based Payment Arrangement, Expense
MiNK Therapeutics, Inc. (INKT) reported Share-based Payment Arrangement, Expense of $422.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $422.00K, a 52.95% decline year-over-year.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $630.00K, a 10.33% increase year-over-year.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $566.00K, a 45.13% increase year-over-year.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $621.00K, a 29.67% decline year-over-year.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $2.65M, a 6.69% decline from fiscal 2024.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $2.84M, a 25.80% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $3.83M, a 26.53% increase from fiscal 2022.
- MiNK Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $3.03M, a 73.47% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $422.00K 10-Q · filed 2026-08-13 | $1.05M 10-Q · filed 2026-08-13 | $1.62M derived: sum of 3 quarters · filed 2026-08-13 | $2.24M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $630.00K 10-Q · filed 2026-05-15 | $1.20M derived: sum of 2 quarters · filed 2026-05-15 | $1.82M derived: sum of 3 quarters · filed 2026-05-15 | $2.71M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.19M derived: sum of 2 quarters · filed 2026-03-31 | $2.08M derived: sum of 3 quarters · filed 2026-08-13 | $2.65M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $621.00K 10-Q · filed 2025-11-14 | $1.52M derived: sum of 2 quarters · filed 2026-08-13 | $2.09M 10-Q · filed 2025-11-14 | $2.48M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $897.00K 10-Q · filed 2026-08-13 | $1.47M 10-Q · filed 2026-08-13 | $1.86M derived: sum of 3 quarters · filed 2026-08-13 | $2.74M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $571.00K 10-Q · filed 2026-05-15 | $961.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.84M derived: sum of 3 quarters · filed 2026-05-15 | $2.69M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.27M derived: sum of 2 quarters · filed 2026-03-31 | $2.12M derived: sum of 3 quarters · filed 2026-03-31 | $2.84M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $883.00K 10-Q · filed 2025-11-14 | $1.73M derived: sum of 2 quarters · filed 2025-11-14 | $2.45M 10-Q · filed 2025-11-14 | $3.52M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $844.00K 10-Q · filed 2025-08-14 | $1.57M 10-Q · filed 2025-08-14 | $2.64M derived: sum of 3 quarters · filed 2025-08-14 | $3.58M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $725.00K 10-Q · filed 2025-05-15 | $1.80M derived: sum of 2 quarters · filed 2025-05-15 | $2.73M derived: sum of 3 quarters · filed 2025-05-15 | $3.63M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $2.01M derived: sum of 2 quarters · filed 2025-03-18 | $2.91M derived: sum of 3 quarters · filed 2025-03-18 | $3.83M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $939.00K 10-Q · filed 2024-11-14 | $1.84M derived: sum of 2 quarters · filed 2024-11-14 | $2.76M 10-Q · filed 2024-11-14 | $3.43M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $898.00K 10-Q · filed 2024-08-13 | $1.82M 10-Q · filed 2024-08-13 | $2.49M derived: sum of 3 quarters · filed 2024-08-13 | $3.26M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $921.00K 10-Q · filed 2024-05-14 | $1.59M derived: sum of 2 quarters · filed 2024-05-14 | $2.36M derived: sum of 3 quarters · filed 2024-05-14 | $3.16M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.44M derived: sum of 2 quarters · filed 2024-03-21 | $2.24M derived: sum of 3 quarters · filed 2024-03-21 | $3.03M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $773.00K 10-Q · filed 2023-11-14 | $772.90K 10-Q · filed 2022-11-03 | $1.57M derived: sum of 2 quarters · filed 2023-11-14 | $2.36M 10-Q · filed 2023-11-14 | $2.36M 10-Q · filed 2022-11-03 | $3.03M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $801.00K 10-Q · filed 2023-08-10 | $800.81K 10-Q · filed 2022-08-15 | $1.59M 10-Q · filed 2023-08-10 | $1.59M 10-Q · filed 2022-08-15 | $2.25M derived: sum of 3 quarters · filed 2023-08-10 | $2.64M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $786.00K 10-Q · filed 2023-05-11 | $785.51K 10-Q · filed 2022-05-13 | $1.45M derived: sum of 2 quarters · filed 2023-05-11 | $1.84M derived: sum of 3 quarters · filed 2023-05-11 | $2.25M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $667.30K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $1.05M derived: sum of 2 quarters · filed 2023-03-24 | $1.46M derived: sum of 3 quarters · filed 2023-03-24 | $1.75M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $387.36K 10-Q · filed 2022-11-03 | $794.66K derived: sum of 2 quarters · filed 2022-11-03 | $1.08M 10-Q · filed 2022-11-03 | $1.11M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $407.30K 10-Q · filed 2022-08-15 | $690.33K 10-Q · filed 2022-08-15 | $724.77K derived: sum of 3 quarters · filed 2022-08-15 | $735.52K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $283.03K 10-Q · filed 2022-05-13 | $317.47K derived: sum of 2 quarters · filed 2022-05-13 | $328.22K derived: sum of 3 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $34.44K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $45.19K derived: sum of 2 quarters · filed 2022-03-18 | $88.00K 10-K · filed 2022-03-18 | ||||
| 2020-09-30 | $10.75K 10-Q · filed 2021-11-29 | $53.56K 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |